Filing excerpt
In November 2025, BMS and Pfizer initiated a patent infringement action against an applicant seeking approval to market apixaban products in the U.S.
Source: Autobound Signal API · 117 signals tracked for Bristol Myers Squibb · updated
Get Bristol Myers Squibb's live signals in Claude or ChatGPT, or by API
What changed at Bristol Myers Squibb this week? Use Autobound signals for bms.com.BMY is engaged in high-stakes patent actions to defend its top-selling drug, Eliquis, from generics. Simultaneously, it is proactively managing future competition by signing a licensing agreement with Dr. Reddy's Laboratories for an Orencia biosimilar, highlighting a complex legal and competitive strategy to protect key revenue streams.
Filing excerpt
In November 2025, BMS and Pfizer initiated a patent infringement action against an applicant seeking approval to market apixaban products in the U.S.
What this signalsFilings often name leadership changes, deals and spending plans.
Competitors
Regions named
sec-10qlitigationMaterialGet every 10-Q signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/be92cff9-ab25-4e4b-bd40-0559a2b865c4 returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.
{
"signal_id": "be92cff9-ab25-4e4b-bd40-0559a2b865c4",
"signal_type": "sec-10q",
"signal_subtype": "litigationMaterial",
"detected_at": "2026-08-04T07:03:39.423+00:00",
"company": {
"name": "Bristol Myers Squibb",
"domain": "bms.com"
},
"data": {
"detail": "BMY is engaged in high-stakes patent actions to defend its top-selling drug, Eliquis, from generics. Simultaneously, it is proactively managing future competition by signing a licensing agreement with Dr. Reddy's Laboratories for an Orencia biosimilar, highlighting a complex legal and competitive strategy to protect key revenue streams.",
"metrics": {
"timeframe": "current_year",
"dollar_context": "Eliquis YTD revenue",
"dollar_millions": 8617
},
"summary": "BMY defends $8.6B drug Eliquis in court and licenses Orencia to competitor Dr. Reddy's",
"excerpts": "In November 2025, BMS and Pfizer initiated a patent infringement action against an applicant seeking approval to market apixaban products in the U.S.",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htm",
"filing_date": "2026-07-30",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/30",
"sales_relevance": "Legal tech opportunity",
"signal_category": "risk",
"regions_mentioned": [
"U.S."
],
"competitors_mentioned": [
"Dr. Reddy's Laboratories"
]
}
}
curl https://signals.autobound.ai/v1/signals/be92cff9-ab25-4e4b-bd40-0559a2b865c4 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.